Introduction Uterine myomas and endometriosis are benign hormone-dependent diseases affecting women of reproductive age. Substantial efforts have been made to develop innovative medical options for treating these gynecologic diseases. Elagolix and relugolix have been approved in some countries for treating endometriosis and myomas, respectively; however, linzagolix (OBE 2109, KLH 2109) is a new oral gonadotropin-releasing hormone (GnRH) antagonist in phase II-III trials. Treatment options for women with contraindications for hormonal therapies or who refuse particular options, are the driving force behind the development of new drugs in this area. Area covered This drug evaluation highlights definitive and preliminary results from previous and ongoing studies of linzagolix for the treatment of endometriosis and myomas. Expert opinion Linzagolix showed a dose-dependent and rapidly reversible action on the pituitary-gonadal axis. In a recent phase II trial (EDELWEISS), linzagolix significantly reduced pain related to endometriosis and improved quality of life at single daily doses of 75-200 mg. The preliminary results of international, double-blind phase III trials (PRIMROSE 1 and 2) reported its efficacy in treating heavy menstrual bleeding related to myomas with a good safety profile. Further studies will determine the necessity of add-back therapy during long-term use of linzagolix.

Linzagolix. a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas / Dababou, Susan; Garzon, Simone; Laganà, Antonio Simone; Ferrero, Simone; Evangelisti, Giulio; Noventa, Marco; D'Alterio, Maurizio Nicola; Palomba, Stefano; Uccella, Stefano; Franchi, Massimo; Barra, Fabio. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - 30:9(2021), pp. 1-9. [10.1080/13543784.2021.1957830]

Linzagolix. a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas

Dababou, Susan;Palomba, Stefano;
2021

Abstract

Introduction Uterine myomas and endometriosis are benign hormone-dependent diseases affecting women of reproductive age. Substantial efforts have been made to develop innovative medical options for treating these gynecologic diseases. Elagolix and relugolix have been approved in some countries for treating endometriosis and myomas, respectively; however, linzagolix (OBE 2109, KLH 2109) is a new oral gonadotropin-releasing hormone (GnRH) antagonist in phase II-III trials. Treatment options for women with contraindications for hormonal therapies or who refuse particular options, are the driving force behind the development of new drugs in this area. Area covered This drug evaluation highlights definitive and preliminary results from previous and ongoing studies of linzagolix for the treatment of endometriosis and myomas. Expert opinion Linzagolix showed a dose-dependent and rapidly reversible action on the pituitary-gonadal axis. In a recent phase II trial (EDELWEISS), linzagolix significantly reduced pain related to endometriosis and improved quality of life at single daily doses of 75-200 mg. The preliminary results of international, double-blind phase III trials (PRIMROSE 1 and 2) reported its efficacy in treating heavy menstrual bleeding related to myomas with a good safety profile. Further studies will determine the necessity of add-back therapy during long-term use of linzagolix.
2021
endometriosis; gnrh antagonist; klh 2109; obe 2109; heavy menstrual bleeding; hormonal therapy; linzagolix; uterine myomas
01 Pubblicazione su rivista::01a Articolo in rivista
Linzagolix. a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas / Dababou, Susan; Garzon, Simone; Laganà, Antonio Simone; Ferrero, Simone; Evangelisti, Giulio; Noventa, Marco; D'Alterio, Maurizio Nicola; Palomba, Stefano; Uccella, Stefano; Franchi, Massimo; Barra, Fabio. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - 30:9(2021), pp. 1-9. [10.1080/13543784.2021.1957830]
File allegati a questo prodotto
File Dimensione Formato  
Dababou_Linzagolix-a new-GnRH-antagonist_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 826.79 kB
Formato Adobe PDF
826.79 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1663030
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 39
social impact